BMS deal is Ambrx's third pharma pact in a year
This article was originally published in Scrip
Executive Summary
Ambrx entered into a third collaboration agreement with Bristol-Myers Squibb in which the partners will use the San Diego-based biotechnology company's protein medicinal chemistry technology to discover and develop novel antibody-drug conjugates (ADCs) for oncology indications.